Vectors Research Management LLC Buys 8,502 Shares of Medtronic PLC $MDT

Vectors Research Management LLC grew its position in Medtronic PLC (NYSE:MDT) by 58.3% during the 3rd quarter, Holdings Channel reports. The firm owned 23,083 shares of the medical technology company’s stock after purchasing an additional 8,502 shares during the quarter. Vectors Research Management LLC’s holdings in Medtronic were worth $2,198,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. AXQ Capital LP boosted its stake in shares of Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares during the last quarter. GC Wealth Management RIA LLC raised its stake in shares of Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after buying an additional 5,734 shares during the last quarter. Merit Financial Group LLC lifted its holdings in Medtronic by 37.5% in the second quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock valued at $4,972,000 after buying an additional 15,561 shares during the period. Verdence Capital Advisors LLC boosted its stake in Medtronic by 22.0% in the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after acquiring an additional 5,296 shares during the last quarter. Finally, World Investment Advisors grew its holdings in Medtronic by 1.9% during the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock worth $13,608,000 after acquiring an additional 2,868 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MDT shares. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research report on Tuesday, December 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. JPMorgan Chase & Co. increased their price objective on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Finally, Leerink Partners set a $120.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Trading Down 2.2%

Shares of Medtronic stock opened at $96.82 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The business has a fifty day simple moving average of $98.99 and a two-hundred day simple moving average of $94.84. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $124.12 billion, a price-to-earnings ratio of 26.10, a P/E/G ratio of 2.61 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).